ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 741,82
0,52%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Allogene Therapeutics Inc (ALLO)

  7. Allogene Therapeutics Inc (ALLO) Actualités

ALLO Allogene Therapeutics Inc

2,91
0,055 (1,93%)
27 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Allogene Therapeutics Inc ALLO NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,055 1,93% 2,91 06:00:03
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,87 2,75 2,93 2,89 2,855
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
26/4/202414:30GLOBEAllogene Therapeutics Awarded Grant from the California..
09/4/202414:30GLOBEAllogene Therapeutics Announces Q2 Investor Conference..
14/3/202421:05GLOBEAllogene Therapeutics Reports Fourth Quarter and Full Year..
12/3/202413:30GLOBEAllogene Therapeutics and Arbor Biotechnologies Announce..
05/3/202414:30GLOBEAllogene Therapeutics to Report Fourth Quarter and Full Year..
28/2/202414:30GLOBEAllogene Therapeutics Announces Participation in the 44th..
16/2/202414:30EDGAR2Form 8-K - Current report
16/2/202414:30GLOBEAllogene Therapeutics to Restate Previously Filed Financial..
31/1/202423:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/1/202423:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/1/202422:11EDGAR2Form 144 - Report of proposed sale of securities
16/1/202422:05GLOBEAllogene Therapeutics Announces Participation in Upcoming..
05/1/202414:00EDGAR2Form 8-K - Current report
04/1/202422:15GLOBEAllogene Therapeutics and Foresight Diagnostics Announce..
04/1/202422:05GLOBEAllogene Therapeutics Announces 2024 Platform Vision to..
03/1/202422:05GLOBEAllogene Therapeutics to Host Conference Call Previewing its..
20/12/202322:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/12/202321:46EDGAR2Form 8-K - Current report
18/12/202322:17EDGAR2Form 144 - Report of proposed sale of securities
09/12/202318:00GLOBEAllogene Therapeutics Presents Comprehensive Safety Data of..
01/12/202314:30GLOBEAllogene Therapeutics Announces Participation in December..
03/11/202317:00GLOBEAllogene Therapeutics Presents Preclinical Data on a Novel..
02/11/202321:41EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
02/11/202321:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202321:03EDGAR2Form 8-K - Current report
02/11/202321:02GLOBEAllogene Therapeutics Reports Third Quarter 2023 Financial..
02/11/202314:00GLOBEAllogene Therapeutics Announces Poster Presentations at the..
30/10/202313:30GLOBEAllogene Therapeutics Announces Participation in November..
26/10/202314:30GLOBEAllogene Therapeutics to Report Third Quarter 2023 Financial..
17/10/202322:34EDGAR2Form 8-K/A - Current report: [Amend]
16/10/202314:31EDGAR2Form 8-K - Current report
16/10/202314:30GLOBEAllogene Therapeutics Appoints Geoffrey Parker as Chief..
27/9/202315:09GLOBEAllogene Therapeutics Announces Three Poster Presentations..
05/9/202314:30GLOBEAllogene Therapeutics Announces Participation in September..
15/8/202301:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/8/202301:28EDGAR2Form 3 - Initial statement of beneficial ownership of..
14/8/202314:30GLOBEAllogene Therapeutics Appoints Earl Douglas as General..
09/8/202322:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/8/202323:15EDGAR2Form 144 - Report of proposed sale of securities
02/8/202322:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/8/202322:04EDGAR2Form 8-K - Current report
02/8/202322:02GLOBEAllogene Therapeutics Reports Second Quarter 2023 Financial..
26/7/202314:30GLOBEAllogene Therapeutics to Report Second Quarter 2023..
11/7/202312:06VWEthereum Blockchain Game Pikamoon Raises $3.6m, Final ICO..
10/7/202316:44VWMassive Gaming Celebrates Global Launch of House of..
10/7/202311:52VWWOW EARN Wallet Offers One-Stop Shop Features, Now Available..
10/7/202311:02VWSwaap v2 Launches: Revolutionizing DeFi Market Making with..
08/7/202316:03VWBritanniacoin’s Official Pre-release: introducing a unique..
06/7/202317:59VWTether Launches USDt On Kava
06/7/202310:03VWOKX to Launch Signal Trading Platform, Empowering Traders..

Dernières Valeurs Consultées

NASDAQ
ALLO
Allogene Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés